中国EV71灭活疫苗上市后安全性监测(2016-2023)
任何原因AEFI报告发生率为40.64/10万剂,严重AEFI为0.30/10万剂,常见疫苗反应为36.55/10万剂,罕见疫苗反应为2.78/10万剂。结论确认EV71疫苗安全性良好,可用于5岁以下儿童预防EV71相关疾病。
要点
- EV71疫苗任何原因AEFI报告发生率为40.64/10万剂。
- 严重AEFI报告发生率为0.30/10万剂,安全性良好。
- 最常见常见反应为发热(30.28/10万剂),主要罕见反应为过敏性皮疹(2.43/10万剂)。
核心结论
- 确认EV71疫苗具有良好的安全性,可安全用于5岁以下儿童预防EV71相关疾病。
研究设计与样本
- 上市后主动监测研究,数据来源于中国国家免疫规划信息系统2016-2023年EV71疫苗AEFI报告及接种剂次数据。
主要发现
- 任何原因AEFI报告发生率为40.64/10万剂,严重AEFI为0.30/10万剂。
- 常见疫苗反应发生率为36.55/10万剂,罕见疫苗反应为2.78/10万剂。
- 最常见的常见疫苗反应为发热,发生率30.28/10万剂;主要罕见疫苗反应为过敏性皮疹,发生率2.43/10万剂。
临床怎么用
- 监测结果支持EV71疫苗在5岁以下儿童中常规接种的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess adverse events following immunization (AEFI) for Enterovirus type 71 (EV71) vaccines in the mainland of China during a post-market-authorization period. METHODS: We obtained AEFI reports for EV71 vaccine during 2016-2023 from the Chinese National Immunization Information System (CNIIS). We obtained EV71 vaccine doses administered data for 2016-2018 and 2019-2023 from provincial immunization information systems or vaccination doctors' reports and from CNIIS, respectively. We analyzed all EV71 vaccine AEFI reports. RESULTS: During the study period, there were 100.95 million doses of EV71 vaccine administered and 41,025 AEFI reports following EV71 vaccination. Incidences of EV71 AEFI reports for any reason, serious AEFI, common vaccine reactions (usually minor), and rare vaccine reactions (possibly serious) were 40.64, 0.30, 36.55, and 2.78 reports per 100,000 doses administered. The most frequently reported common vaccine reaction was fever; allergic rash was the main reported rare vaccine reaction; respective incidences were 30.28 and 2.43 per 100,000 doses. CONCLUSIONS: A favorable safety profile of EV71 vaccine was confirmed. EV71 vaccine can be used safely to prevent EV71-related diseases in children under 5 years old.
引用
- Li K, Li Y, Zhang L, et al. Post-marketing surveillance of adverse events following enterovirus type 71 inactivated vaccine in China, 2016-2023. Vaccine. 2026. PMID: 41825189. doi:10.1016/j.vaccine.2026.128443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。